Patients with NASH displayed elevated levels of plasmatic S100A8 [111], S100A9 [116] and S100A11 [65,110], while mRNA expression of several S100 isoforms, i.e., S100A3, S100A4, S100A6, S100A10, S100A11, S100A13 and S100A16, appears to be upregulated in the hepatic tissues of patients with NASH, as assessed by in silico analyses of publicly available datasets (Figure 5). Here, S100A16 is linked to metabolic dysfunction-associated steatohepatitis.